Cargando…

Update on Retinal Drug Toxicities

PURPOSE OF REVIEW: This review aims to provide an update on the clinical presentations and diagnostic findings of drug-induced retinal toxicities. RECENT FINDINGS: Several newly FDA-approved medications have been associated with acute retinal toxicities, including brolucizumab, MEK inhibitors, ulixe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, S. Tammy, Ponugoti, Arathi, Deaner, Jordan D., Vajzovic, Lejla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688906/
https://www.ncbi.nlm.nih.gov/pubmed/34956737
http://dx.doi.org/10.1007/s40135-021-00277-x
_version_ 1784618444682952704
author Hsu, S. Tammy
Ponugoti, Arathi
Deaner, Jordan D.
Vajzovic, Lejla
author_facet Hsu, S. Tammy
Ponugoti, Arathi
Deaner, Jordan D.
Vajzovic, Lejla
author_sort Hsu, S. Tammy
collection PubMed
description PURPOSE OF REVIEW: This review aims to provide an update on the clinical presentations and diagnostic findings of drug-induced retinal toxicities. RECENT FINDINGS: Several newly FDA-approved medications have been associated with acute retinal toxicities, including brolucizumab, MEK inhibitors, ulixertinib, and FGFR inhibitors. Additionally, as previously believed-to-be well-tolerated medications, such as pentosan sulfate sodium, anti-retroviral therapies, and certain intraoperative ocular medications, are used more frequently or for longer periods of time, associated toxic retinopathies and inflammatory reactions have been reported. Finally, advances in ocular imaging have revealed novel findings in hydroxychloroquine and tamoxifen maculopathies. SUMMARY: Discovery of new medications, increased frequency of use, and longer-term use have led to increased reports of retinal toxicities. Advances in retinal imaging have allowed for earlier detection of subclinical changes associated with these medications, which may help prevent progression of disease. However, more research is needed to determine the point at which vision loss becomes irreversible. Risks and benefits must be assessed prior to discontinuation of the offending, but potentially lifesaving, therapy.
format Online
Article
Text
id pubmed-8688906
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-86889062021-12-21 Update on Retinal Drug Toxicities Hsu, S. Tammy Ponugoti, Arathi Deaner, Jordan D. Vajzovic, Lejla Curr Ophthalmol Rep Retina (R Goldhardt, Section Editor) PURPOSE OF REVIEW: This review aims to provide an update on the clinical presentations and diagnostic findings of drug-induced retinal toxicities. RECENT FINDINGS: Several newly FDA-approved medications have been associated with acute retinal toxicities, including brolucizumab, MEK inhibitors, ulixertinib, and FGFR inhibitors. Additionally, as previously believed-to-be well-tolerated medications, such as pentosan sulfate sodium, anti-retroviral therapies, and certain intraoperative ocular medications, are used more frequently or for longer periods of time, associated toxic retinopathies and inflammatory reactions have been reported. Finally, advances in ocular imaging have revealed novel findings in hydroxychloroquine and tamoxifen maculopathies. SUMMARY: Discovery of new medications, increased frequency of use, and longer-term use have led to increased reports of retinal toxicities. Advances in retinal imaging have allowed for earlier detection of subclinical changes associated with these medications, which may help prevent progression of disease. However, more research is needed to determine the point at which vision loss becomes irreversible. Risks and benefits must be assessed prior to discontinuation of the offending, but potentially lifesaving, therapy. Springer US 2021-12-21 2021 /pmc/articles/PMC8688906/ /pubmed/34956737 http://dx.doi.org/10.1007/s40135-021-00277-x Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Retina (R Goldhardt, Section Editor)
Hsu, S. Tammy
Ponugoti, Arathi
Deaner, Jordan D.
Vajzovic, Lejla
Update on Retinal Drug Toxicities
title Update on Retinal Drug Toxicities
title_full Update on Retinal Drug Toxicities
title_fullStr Update on Retinal Drug Toxicities
title_full_unstemmed Update on Retinal Drug Toxicities
title_short Update on Retinal Drug Toxicities
title_sort update on retinal drug toxicities
topic Retina (R Goldhardt, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688906/
https://www.ncbi.nlm.nih.gov/pubmed/34956737
http://dx.doi.org/10.1007/s40135-021-00277-x
work_keys_str_mv AT hsustammy updateonretinaldrugtoxicities
AT ponugotiarathi updateonretinaldrugtoxicities
AT deanerjordand updateonretinaldrugtoxicities
AT vajzoviclejla updateonretinaldrugtoxicities